Insomnia Drugs and Heart Interactions: Two Case Reports Patients Must Know

When Insomnia Drugs Interact With the Heart: Two Case Reports Every Patient Should Know

A 35-year-old woman with generalized anxiety disorder and insomnia nearly ran into serious cardiac trouble because of how her sleep medications mixed with her heart rhythm drugs. Her case, published in Cureus in 2026, joins a second report from Am J Case Rep describing a patient whose severe insomnia was actually the first sign of a blood clot in the brain. Together, they show why insomnia pharmacotherapy deserves careful, individualized decisions rather than routine prescriptions.

How Insomnia Medications Interfered With a Heart Rhythm Drug

Neurologists and pharmacologists at California Health Sciences University and Thriving Minds Psychiatric Services in California described a patient managing two conditions at once: anxiety with insomnia, and sick sinus syndrome — a disorder in which the heart’s natural pacemaker fails to keep a steady rhythm. After a catheter ablation for supraventricular tachycardia, she took metoprolol, a beta-blocker that slows heart rate, alongside a psychiatric regimen of bupropion, hydroxyzine, melatonin, and intermittent quetiapine.

The problem is that psychiatric drugs rarely act only on the brain. Hydroxyzine, an antihistamine frequently used off-label for insomnia, blocks the hERG potassium channel in cardiac muscle. That blockade prolongs the QT interval — the portion of the cardiac cycle visible on an ECG — and creates fertile ground for torsades de pointes, a potentially lethal arrhythmia. Quetiapine, an antipsychotic also used off-label as a sedative, carries its own conduction effects and may have interfered with her antiarrhythmic therapy.

Bupropion presented a subtler danger. It inhibits CYP2D6, a liver enzyme responsible for metabolizing flecainide, a sodium-channel-blocking antiarrhythmic. When CYP2D6 is inhibited, flecainide levels climb, and a drug meant to stabilize rhythm can instead destabilize it. Her clinicians responded by stopping quetiapine entirely, restricting hydroxyzine to low doses, and keeping melatonin — which has no meaningful cardiac conduction effects — in place, supported by stress testing before further medication changes.

When Severe Insomnia Was the First Symptom of a Stroke

A second case, from Dr. Suliman Fakeeh Hospital in Jeddah, Saudi Arabia, illustrates the opposite direction of risk: not insomnia drugs causing harm, but insomnia as a warning sign. A 37-year-old woman with no psychiatric history and no thrombotic risk factors arrived with acute insomnia, agitation, emotional lability, and aggression. Her brain MRI, spinal fluid analysis, and infection workup all came back normal. Physicians admitted her under a working diagnosis of acute polymorphic psychotic disorder.

Six days later she lost consciousness and had generalized tonic-clonic seizures. Urgent imaging revealed a right high-parietal hemorrhage, and venous imaging confirmed cerebral venous thrombosis — a clot in the superficial superior cerebral vein, an uncommon stroke type that preferentially affects young adults. Sleeplessness and agitation, in other words, were brain responses to venous pressure and impaired drainage, not a primary psychiatric illness. With antiepileptics and anticoagulation, both her neurological and psychiatric symptoms gradually improved.

What This Means for Insomnia Treatment Decisions

These cases converge on one message: sedation is not the same as treatment. Hydroxyzine and low-dose quetiapine are widely prescribed for sleep, yet both carry QT-prolonging risk, and quetiapine adds metabolic and drug-interaction burdens. Melatonin, by contrast, works through MT1 and MT2 receptors in the suprachiasmatic nucleus and carries minimal cardiac risk — a reason it survived this patient’s medication review untouched. Readers interested in how orexin blockers compare with traditional sleeping pills can find a deeper discussion of newer targets with fewer next-day effects.

The Saudi case adds a diagnostic caution. Insomnia accompanied by sudden agitation, personality change, or aggression in someone without psychiatric history warrants neurological consideration — especially when symptoms begin abruptly. Normal early imaging does not exclude venous disease; dedicated venous imaging may be needed. For most insomnia patients, behavioral approaches remain first-line, as covered in our guide to sleep restriction therapy, and evidence-based relaxation methods such as brief breathing exercises that lower cortisol carry no pharmacological interaction risk at all.

Practical Applications

• If you take an antiarrhythmic such as flecainide or have any conduction disorder, tell your prescriber before starting hydroxyzine, quetiapine, or bupropion for sleep.
• Ask whether your insomnia drug inhibits CYP2D6 — bupropion, fluoxetine, and paroxetine are the strongest offenders.
• Melatonin is the cardiac-safest pharmacological sleep aid in patients with arrhythmia, though it is modest in effect.
• Sudden-onset insomnia with behavioral change and no prior psychiatric history deserves prompt medical evaluation rather than a sedative prescription.
• Request an ECG (QT check) when combining multiple QT-prolonging drugs, a point also relevant to readers tracking how sleep predicts heart disease risk.

Frequently Asked Questions

Is hydroxyzine safe for insomnia if I have a heart condition?

Not necessarily. Hydroxyzine can prolong the QT interval and raise arrhythmia risk, so patients with conduction disease or those on antiarrhythmics should use it only at the lowest effective dose under cardiology-aware supervision.

Why did doctors stop quetiapine in the cardiac case?

Quetiapine may interfere with flecainide’s antiarrhythmic action and adds its own conduction effects, so removing it minimized the combined risk of dangerous rhythm disturbances.

Can insomnia be a sign of something more serious than stress?

Yes. In rare cases, abrupt insomnia with agitation and personality change signals neurological disease such as cerebral venous thrombosis, even when initial scans look normal.

Was melatonin considered risky for this patient?

No. Melatonin has no clinically meaningful effect on cardiac conduction, so it was continued — making it a preferred option when insomnia treatment must spare the heart.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42698192/
https://pubmed.ncbi.nlm.nih.gov/42695092/
https://pubmed.ncbi.nlm.nih.gov/42694570/
https://pubmed.ncbi.nlm.nih.gov/42689090/
https://pubmed.ncbi.nlm.nih.gov/42688312/